Stein CA, Castanotto D. FDA-approved oligonucleotide therapies in 2017. Mol Ther Elsevier Ltd. 2017;25:1069–75.

Article  CAS  Google Scholar 

Kim CM, Smolke CD. Biomedical applications of RNA-based devices. Curr Opin Biomed Eng. 2017;4:106–15.

Article  PubMed  PubMed Central  Google Scholar 

Kaczmarek JC, Kowalski PS, Anderson DG. Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Med. 2017;9:60.

Article  PubMed  PubMed Central  Google Scholar 

Mollocana-Lara EC, Ni M, Agathos SN, Gonzales-Zubiate FA. The infinite possibilities of RNA therapeutics. J Ind Microbiol Biotechnol. 2021;48: kuab063.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19(10):673–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Igarashi J, Niwa Y, Sugiyama D. Research and development of oligonucleotide therapeutics in Japan for rare diseases. Futur Rare Dis. 2022;2:1–14.

Google Scholar 

Mullard A. FDA approves fifth RNAi drug - Alnylam’s next-gen hATTR treatment. Nat Rev Drug Discov. 2022;21(8):548–9.

PubMed  Google Scholar 

Bireley JD, Morren JA. CNM-Au8: an experimental agent for the treatment of amyotrophic lateral sclerosis (ALS). Expert Opin Investig Drugs. 2023;32:677–83 (Taylor & Francis).

Article  CAS  PubMed  Google Scholar 

Ramachandran S, Satapathy SR, Dutta T. Delivery strategies for mRNA vaccines. Pharmaceut Med. 2022;36:11–20.

CAS  PubMed  PubMed Central  Google Scholar 

Kulkarni JA, Witzigmann D, Thomson SB, Chen S, Leavitt BR, Cullis PR, et al. The current landscape of nucleic acid therapeutics. Nat Nanotechnol. 2021;16:630–43.

Article  ADS  CAS  PubMed  Google Scholar 

Sinning D, Landmesser U. Low-density lipoprotein-cholesterol lowering strategies for prevention of atherosclerotic cardiovascular disease: focus on siRNA Treatment targeting PCSK9 (Inclisiran). Curr Cardiol Rep. 2020;22:176.

Article  PubMed  PubMed Central  Google Scholar 

Kronenberg F. Lipoprotein(a). In: von Eckardstein A, Binder CJ, editors. Prev treat atheroscler improv state-of-the-art manag search nov targets. Cham: Springer International Publishing; 2022. p. 201–32.

Google Scholar 

Cegla J, France M, Marcovina SM, Neely RDG. Lp(a): When and how to measure it. Ann Clin Biochem. 2021;58:16–21.

Article  CAS  PubMed  Google Scholar 

Nissen SE, Wolski K, Balog C, Swerdlow DI, Scrimgeour AC, Rambaran C, et al. Single ascending dose study of a short interfering RNA targeting Lipoprotein(a) production in individuals with elevated plasma Lipoprotein(a) levels. J Am Med Assoc. 2022;327:1679–87.

Article  CAS  Google Scholar 

Grundy SM. Correction. (Journal of the American College of Cardiology (2019) 73(24) (3168–3209), (S0735109718390338), (https://doi.org/10.1016/j.jacc.2018.11.002)). J Am Coll Cardiol. 2019;73:3234–7.

Banach M, Burchardt P, Chlebus K, Dobrowolski P, Dudek D, Dyrbuś K, et al. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci. 2021;17:1447–547.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kronenberg F. Human genetics and the causal role of Lipoprotein(a) for various diseases. Cardiovasc Drugs Ther. 2016;30:87–100.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Luke MM, Shiffman D, Devlin JJ. Genetic variants in the Apolipoprotein(a) gene and coronary heart disease. Circ Cardiovasc Genet. 2011;4:565–73 (American Heart Association).

Article  CAS  PubMed  Google Scholar 

Kim Y-K. RNA therapy: rich history, various applications and unlimited future prospects. Exp Mol Med. 2022;54:455–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet. 2022;23:265–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bonham MA, Brown S, Boyd AL, Brown PH, Bruckenstein DA, Hanvey JC, et al. An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers. Nucleic Acids Res. 1995;23:1197–203 (England).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Egli M, Manoharan M. Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Res. 2023;51:2529–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

European Medicines Agency. Tegsedi. Inotersen. 2023. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tegsedi

European Medicines Agency. EMEA-002403-PIP01–18 - paediatric investigation plan. Tofersen. 2018. Available from: https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002403-pip01-18

European Medicines Agency. EU/3/16/1732 - orphan designation for treatment of amyotrophic lateral sclerosis. Tofersen. 2019. Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1732

European Medicines Agency. EU/3/20/2282 - orphan designation for treatment of Duchenne muscular dystrophy. Viltolarsen. 2023. Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2282

European Medicines Agency. Spinraza. Nusinersen. 2023. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/spinraza

Gait MJ, Agrawal S. Introduction and history of the chemistry of nucleic acids therapeutics BT—antisense RNA design, delivery, and analysis. In: Arechavala-Gomeza V, Garanto A, editors. Methods Mol Biol. New York: Springer, US; 2022. p. 3–31.

Google Scholar 

Xu W, Jiang X, Huang L. RNA interference technology. Compr Biotechnol. Elsevier; 2019. p. 560–75.

Zogg H, Singh R, Ro S. Current advances in RNA therapeutics for human diseases. Int J Mol Sci. 2022.

Al Musaimi O, Al Shaer D, Albericio F, de la Torre BG. 2022 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals (Basel). Switzerland; 2023;16.

European Medicines Agency. Amvuttra. Vutrisiran. 2024. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/amvuttra

European Medicines Agency. Onpattro. Patisiran. 2023. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tegsedi

European Medicines Agency. Givlaari. Givosiran. 2023. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tegsedi

European Medicines Agency. Oxlumo. Lumasiran. 2023. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tegsedi

European Medicines Agency. Leqvio. Inclisiran. 2023. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tegsedi

Qin S, Tang X, Chen Y, Chen K, Fan N, Xiao W, et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct Target Ther. 2022;7:166.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duan Q, Hu T, Zhu Q, Jin X, Chi F, Chen X. How far are the new wave of mRNA drugs from us? mRNA product current perspective and future development. Front Immunol. 2022.

European Medicines Agency. Spikevax (previously COVID-19 Vaccine Moderna). 2023. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/spikevax-previously-covid-19-vaccine-moderna

European Medicines Agency. Comirnaty. 2023. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty

Blom DJ, Marais AD, Moodley R, van der Merwe N, van Tonder A, Raal FJ. RNA-based therapy in the management of lipid disorders: a review. Lipids Health Dis. 2022. https://doi.org/10.1186/s12944-022-01649-3.

Article  PubMed  PubMed Central  Google Scholar 

Jin HY, Gonzalez-Martin A, Miletic AV, Lai M, Knight S, Sabouri-Ghomi M, et al. Transfection of microRNA Mimics Should Be Used with Caution. Front Genet. 2015. https://doi.org/10.3389/fgene.2015.00340.

Article  PubMed  PubMed Central  Google Scholar 

Rupaimoole R, Han H-D, Lopez-Berestein G, Sood AK. MicroRNA therapeutics: principles, expectations, and challenges. Chin J Cancer. 2011;30(6):368–70.

Article  PubMed  PubMed Central  Google Scholar 

Lam JKW, Chow MYT, Zhang Y, Leung SWS. siRNA Versus miRNA as Therapeutics for Gene Silencing. Mol Ther Nucleic Acids. 2015;4: e252 (United States).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010;466:835–40.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9:102–14.

Article  CAS  PubMed  Google Scholar 

Hanna J, Hossain GS, Kocerha J. The Potential for microRNA Therapeutics and Clinical Research. Front Genet. 2019. https://doi.org/10.3389/fgene.2019.00478.

Article  PubMed  PubMed Central  Google Scholar 

Guerriaud M, Kohli E. RNA-based drugs and regulation: toward a necessary evolution of the definitions issued from the European union legislation. Front Med. 2022.

Robertson B, Dalby AB, Karpilow J, Khvorova A, Leake D, Vermeulen A. Specificity and functionality of microRNA inhibitors. Silence. 2010;1:10.

Article  PubMed  PubMed Central  Google Scholar 

Kuijper EC, Bergsma AJ, Pijnappel WWMP, Aartsma-Rus A. Opportunities and challenges for antisense oligonucleotide therapies. J Inherit Metab Dis. 2021;44:72–87 (John Wiley & Sons, Ltd).

Article  CAS  PubMed  Google Scholar 

Mansoor M, Melendez AJ. Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics. Gene Regul Syst Bio. 2008;2: GRSB.S418 (SAGE Publications Ltd STM).

Article